Stockreport

Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program

Celyad Oncology SA - American Depositary Shares  (CYAD) 
US:NASDAQ Investor Relations: celyad.com/en/investors
PDF Regulators accept proposal to utilize OptimAb manufacturing process, which enriches for T cells with memory-like phenotype, with CYAD-01 under current IND applicationFDA [Read more]